Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BOTOX Effects on Seizure Severity and Susceptibility

NCT05605756 is registered in ClinicalTrials.gov with Beth Israel Deaconess Medical Center as lead sponsor.

NCT NCT05605756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05605756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BOTOX Effects on Seizure Severity and Susceptibility
Lead sponsor
Beth Israel Deaconess Medical Center
Phase
Phase 4
Overall status
Terminated
Start date
March 1, 2023
Completion date
December 1, 2024
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug-resistant focal seizure